Clinical Trials
21 trialsNCT02188264 2025-02-11
Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT03213691 2025-02-05
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Completed
NCT01306045 2024-10-01
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00551070 2020-12-03
Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01222689 2020-07-31
Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01287130 2019-12-17
AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01011933 2019-07-23
Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01143402 2017-07-26
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
National Cancer Institute (NCI)
Phase 2 Completed
NCT01229150 2017-05-23
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00559949 2017-01-30
Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine
National Cancer Institute (NCI)
Phase 2 Completed
NCT00553332 2016-04-22
Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01658943 2016-03-09
S1115
National Cancer Institute (NCI)
Phase 2 Completed
NCT01061749 2016-01-25
Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies
National Cancer Institute (NCI)
Phase 1 Completed
NCT00888134 2016-01-15
Selumetinib in Cancers With BRAF Mutations
National Cancer Institute (NCI)
Phase 2 Completed
NCT01206140 2015-10-05
Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01333475 2015-09-30
MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01085214 2015-08-19
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00866177 2015-08-11
MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00588809 2015-08-05
Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT01217450 2014-05-29
Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00604721 2014-05-28
Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer
National Cancer Institute (NCI)
Phase 2 Completed